mRNA Vaccine CDMO Market Insights and Growth Patterns Through 2035
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Projected To Expand During 2026–2030?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size has experienced rapid growth in recent years. It is anticipated to increase from $8.41 billion in 2025 to $9.68 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.1%. This historical expansion can be attributed to elements such as COVID-19 vaccine programs, the rise of biotech startups, constrained in-house manufacturing capacity, a surge in contract manufacturing, and the quick validation of mRNA platforms.
The market for messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organizations (CDMOs) is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $17.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this anticipated growth include the development of mRNA cancer vaccines, the rise of personalized vaccines, an increase in CDMO collaborations, the need for swift manufacturing at scale, and a growing number of mRNA therapies in development. Key trends anticipated during this period encompass services related to lipid nanoparticle formulation, accelerated mRNA process scaling, outsourced integrated fill-finish operations, adaptable modular vaccine manufacturing facilities, and comprehensive end-to-end mRNA development solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33214&type=smp
What Important Drivers Are Powering The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Growth?
The mRNA vaccine CDMO market is projected to expand due to the increasing occurrence of infectious and emerging diseases. These diseases are defined as conditions stemming from pathogenic microorganisms, which either spread quickly or manifest newly, often influenced by environmental shifts, urbanization, and enhanced global connections. Increased global travel, higher population densities, and interwoven supply chains have expedited the spread of pathogens, leading to more frequent, extensive, and challenging-to-control disease outbreaks. mRNA vaccine CDMOs are vital in tackling these issues, facilitating the swift development, scalable manufacturing, and adaptable production of vaccines essential for confronting evolving infectious threats. Given the need for specialized manufacturing infrastructure and technical know-how for mRNA technologies, vaccine developers increasingly depend on contract development and manufacturing organizations to speed up development and guarantee production readiness during outbreaks. As an illustration, the World Health Organization (WHO), a Switzerland-based United Nations’ specialized agency for global health, reported in May 2024 that by 30 April 2024, global dengue cases exceeded 7.6 million, with 3.4 million confirmed cases, over 16,000 severe cases, and more than 3,000 deaths. This surge was especially noticeable in the Region of the Americas, where cases reached over seven million by April 2024, surpassing the entire 2023 annual total of 4.6 million cases. Consequently, the increasing occurrence of infectious and emerging diseases is a key factor propelling the expansion of the mRNA vaccine CDMO market.
Which Segment Divisions Form The Structure Of The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development; Manufacturing; Analytical And Quality Control; Fill Finish; Packaging; Other Service Types
2) By Vaccine Type: COVID-19 Vaccines; Cancer Vaccines; Infectious Disease Vaccines; Other Vaccine Types
3) By Scale of Operation: Preclinical; Clinical; Commercial
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Formulation Optimization; Cell Line Development; Upstream Process Development; Process Scale-Up
2) By Manufacturing: Lipid Nanoparticle Production; Enzymatic Capping; Purification Process
3) By Analytical And Quality Control: Potency Testing; Purity Analysis; Stability Testing; Identity Testing; Microbial Testing
4) By Fill Finish: Aseptic Filling; Vial Filling; Syringe Filling; Lyophilization
5) By Packaging: Primary Packaging; Secondary Packaging; Labeling Operations; Cold Chain Packaging; Unit Dose Packaging
6) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Contract Development Services; Consulting Services; Supply Chain Management
What Trends Are Impacting The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
Leading firms within the mRNA vaccine CDMO market are increasingly prioritizing cutting-edge advancements, including phase-appropriate GMP mRNA contract development and manufacturing solutions, to expedite preclinical and IND-enabling development while upholding regulatory-compliant quality standards and achieving quicker turnaround times. This approach, known as phase-appropriate GMP-like mRNA manufacturing, describes a production method intended to provide premium, regulatory-conscious mRNA material suitable for preclinical and initial development phases, circumventing the expenses and operational intricacies typically linked with comprehensive GMP manufacturing. As an illustration, in May 2025, GenScript Biotech Corporation, a global biotechnology reagents and services provider based in China, introduced a GMP-like mRNA manufacturing service designed to aid preclinical and IND-enabling development. This offering yields high-quality, regulatory-aware mRNA, featuring faster delivery and decreased expenditures when contrasted with conventional full GMP manufacturing, exemplifying the rising need for adaptable, phase-appropriate CDMO solutions within the mRNA vaccine market.
Which Firms Are Competing In The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH
Access The Complete Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report:
Which Area Represents The Largest Portion Of The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the mRNA vaccine contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report for Deeper Competitive Insights
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
